Osteogenesis imperfecta (OI) is the most prevalent heritable bone fragility disorder in
children. It has been known for three decades that the majority of individuals with OI have …

Osteogenesis imperfecta (OI) is the most common inherited form of bone fragility and
includes a heterogenous group of genetic disorders which most commonly result from …

ABSTRACT This 21‐week, open‐label, phase 2a trial aimed to evaluate the
pharmacodynamics and safety of multiple, escalating infusions of BPS804, a neutralizing …

Context Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone
fragility largely caused by defects in structure, synthesis, or post-translational processing of …

Atypical femoral fractures (AFFs) are uncommon and have been associated particularly with
long term antiresorptive therapy, including bisphosphonates. Although the pathogenesis of …

Several recent case reports have suggested that bisphosphonate treatment in individuals
with osteogenesis imperfecta (OI) is causally related to atypical femur fractures. However, it …

Osteogenesis imperfecta is a heritable group of collagen-related disorders that affects up to
50,000 people in the United States. Although the disease is most symptomatic in childhood …

Introduction Healing of complete, atypical femoral fractures is thought to be impaired, but the
evidence is weak and appears to be based on the delayed healing observed in patients with …

Context: The short-term benefits of bisphosphonates (BPs) are evident in the treatment of
children with osteogenesis imperfecta (OI), but some concerns related to long-term effects …

Purpose Osteogenesis imperfecta (OI) is characterized by increased bone fragility and
susceptibility for fractures. A few studies described and compared treatment modalities for …